I

Inhibrx Biosciences, Inc. (INBX)

NMS – Real vaqt narxi. Valyuta: USD

108.65

-18.93 (-14.84%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

I

Inhibrx Biosciences, Inc. (INBX)

NMS – Real vaqt narxi. Valyuta: USD

108.65

-18.93 (-14.84%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc.'s (NYSE:MRK) Keytruda (pembrolizumab) for treating head and neck cancer.

11.05.2026

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.

11.05.2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.

08.05.2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m.

23.04.2026

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.

22.04.2026

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart's Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts.

22.04.2026

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.

21.04.2026

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). As of April 10, 2026, the cutoff date, the CRC cohort continued to demonstrate a compelling signal of activity in a heavily pretreated patient population.

19.03.2026

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

02.03.2026

Inhibrx Announces Participation in Upcoming Scientific Conference

SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference: ESMO Sarcoma and Rare Cancers Congress March 12th- 14th, 2026; Lugano Switzerland Title: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing Sarcoma Abstract number: 84MO Lead Author: Rashmi Chugh, M.D. (Presenting author: Ana Sebio, M.D.

Search stocks

Inhibrx Biosciences, Inc. (INBX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Videolar

No Data

Press-relizlar

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Inhibrx Announces Participation in Upcoming Scientific Conference